Search

Your search keyword '"Linssen, GCM"' showing total 83 results

Search Constraints

Start Over You searched for: Author "Linssen, GCM" Remove constraint Author: "Linssen, GCM"
83 results on '"Linssen, GCM"'

Search Results

1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

2. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

3. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

4. Contemporary use of devices in chronic heart failure in the Netherlands

5. Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF

10. Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

11. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial

12. Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 in patients with chronic heart failure

13. Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II)

14. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

15. Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

16. Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial

17. Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials

18. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

19. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.

20. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.

21. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study.

22. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.

23. Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials.

24. Invasiveness of previous treatment for peripheral arterial disease and risk of adverse cardiac events after coronary stenting.

25. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF.

26. First myocardial infarction in patients with premature coronary artery disease: insights into patient characteristics and outcome after treatment with contemporary stents.

27. Impact of premature coronary artery disease on adverse event risk following first percutaneous coronary intervention.

28. Identifying distinct clinical clusters in heart failure with mildly reduced ejection fraction.

29. Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials.

30. Heart failure treatment in patients with and without obesity with an ejection fraction below 50.

31. The effects of positive psychology interventions on well-being and distress in patients with cardiovascular diseases: A systematic review and Meta-analysis.

32. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.

33. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.

34. Phenotypic patient profiling for improved implementation of guideline-directed medical therapy: An exploratory analysis in a large real-world chronic heart failure cohort.

35. Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial disease.

36. Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-Comers.

37. Thirst in stable heart failure patients; time to reconsider fluid restriction and prescribed diuretics.

38. Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials.

39. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.

40. Non-cardiovascular medication and readmission for heart failure: an observational cohort study.

41. Diabetes and treatment of chronic heart failure in a large real-world heart failure population.

42. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study.

43. Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction.

44. Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial.

45. Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry.

46. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction.

47. Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials.

48. Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial.

49. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.

50. Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial.

Catalog

Books, media, physical & digital resources